Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.64 |
| ▸ | DPP8 | Q6V1X1 | 13/20 | 0.64 |
| ▸ | DPP9 | Q86TI2 | 8/20 | 0.64 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.64 |
| ▸ | PREP | P48147 | 2/20 | 0.61 |
| ▸ | FAP | Q12884 | 6/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719969 | 1.00 | DPP4 (0.64) | DPP4DPP8DPP9DPP7PREP | |
| SCHEMBL720421 | 0.86 | DPP4 (0.63) | DPP4DPP8DPP9DPP7PREP | |
| SCHEMBL720420 | 0.86 | DPP4 (0.63) | DPP4DPP8DPP9DPP7PREP | |
| SCHEMBL14392567 | 0.79 | DPP4 (0.80) | DPP4DPP8DPP9DPP7PREP | |
| SCHEMBL6453066 | 0.78 | DPP4 (1.00) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL9450506 | 0.77 | DPP4 (0.50) | DPP4DPP8DPP9DPP7PREP | |
| SCHEMBL5530143 | 0.77 | DPP4 (0.59) | DPP4DPP8DPP7PREP | |
| SCHEMBL719153 | 0.76 | DPP4 (0.62) | DPP4DPP8DPP9DPP7PREP | |
| SCHEMBL14392722 | 0.76 | DPP4 (1.00) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL7444796 | 0.76 | DPP4 (0.52) | DPP4DPP8DPP9DPP7FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053222-A1 | Novel Metabolic Disease Therapy | THE UNIVERSITY OF SYDNEY (AU) | 2012-03-01 | — | — | US | claimed |
| US-20100081701-A1 | FAP inhibitors | VANTIA LIMITED (GB) | 2010-04-01 | — | — | US | claimed |
| EP-1919864-A2 | FAP INHIBITORS | Ferring B.V. (NL) | 2008-05-14 | — | — | EP | claimed |
| WO-2007085895-A2 | FAP INHIBITORS | FERRING B.V. (US) | 2007-08-02 | — | — | WO | claimed |
| EP-1760076-A1 | FAP Inhibitors | FERRING B.V. (NL) | 2007-03-07 | — | — | EP | claimed |
| US-8183280-B2 | FAP inhibitors | VANTIA LIMITED (GB) | 2012-05-22 | — | — | US | disclosed |
| US-8183280-B2 | FAP inhibitors | VANTIA LIMITED (GB) | 2012-05-22 | — | — | US | disclosed |
| US-8183280-B2 | FAP inhibitors | VANTIA LIMITED (GB) | 2012-05-22 | — | — | US | disclosed |
| US-20120053222-A1 | Novel Metabolic Disease Therapy | THE UNIVERSITY OF SYDNEY (AU) | 2012-03-01 | — | — | US | disclosed |
| EP-2389176-A1 | NOVEL METABOLIC DISEASE THERAPY | The University Of Sydney (AU) | 2011-11-30 | — | — | EP | disclosed |
| US-20110253961-A1 | Combined Guardrail and Cable Safety Systems | TRINITY INDUSTRIES, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| WO-2010083570-A1 | NOVEL METABOLIC DISEASE THERAPY | THE UNIVERSITY OF SYDNEY (AU) | 2010-07-29 | — | — | WO | disclosed |
| US-20100081701-A1 | FAP inhibitors | VANTIA LIMITED (GB) | 2010-04-01 | — | — | US | disclosed |
| US-20100081701-A1 | FAP inhibitors | VANTIA LIMITED (GB) | 2010-04-01 | — | — | US | disclosed |
| US-20100081701-A1 | FAP inhibitors | VANTIA LIMITED (GB) | 2010-04-01 | — | — | US | disclosed |
| WO-2007085895-A2 | FAP INHIBITORS | FERRING B.V. (US) | 2007-08-02 | — | — | WO | disclosed |
| EP-1760076-A1 | FAP Inhibitors | FERRING B.V. (NL) | 2007-03-07 | — | — | EP | disclosed |
| EP-1760076-A1 | FAP Inhibitors | FERRING B.V. (NL) | 2007-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081701-A1 | FAP inhibitors | FAP, APC, SERPINB1 | DPP4 256/4885DPP8 227/4885DPP9 59/4885 |
| US-20120053222-A1 | Novel Metabolic Disease Therapy | FAP, G6PC1, FBP1 | DPP4 11/4885DPP8 56/4885DPP9 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.